Obseva SA (NASDAQ:OBSV) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 1,750,000 shares, an increase of 28.7% from the August 15th total of 1,360,000 shares. Based on an average daily trading volume, of 925,000 shares, the short-interest ratio is presently 1.9 days. Approximately 5.1% of the shares of the stock are short sold.

OBSV stock traded up $0.13 during mid-day trading on Wednesday, hitting $2.90. 28,317 shares of the company were exchanged, compared to its average volume of 781,498. The firm has a market cap of $132.96 million, a P/E ratio of -1.23 and a beta of 0.84. Obseva has a 1-year low of $1.63 and a 1-year high of $9.62. The firm’s 50 day simple moving average is $2.73 and its 200 day simple moving average is $3.24. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.52 and a current ratio of 2.52.

Obseva (NASDAQ:OBSV) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.38) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.04. On average, equities research analysts predict that Obseva will post -1.62 EPS for the current fiscal year.

A number of equities research analysts recently issued reports on OBSV shares. Wedbush reiterated a “buy” rating and set a $30.00 target price on shares of Obseva in a research report on Friday, August 14th. SVB Leerink decreased their target price on Obseva from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, July 7th. Zacks Investment Research lowered shares of Obseva from a “buy” rating to a “hold” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. cut shares of Obseva from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $5.00 in a research note on Tuesday, July 7th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Obseva in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.25.

A number of hedge funds have recently made changes to their positions in the business. Logos Global Management LP bought a new stake in Obseva in the second quarter valued at approximately $6,862,000. Rock Springs Capital Management LP boosted its holdings in Obseva by 77.3% in the 1st quarter. Rock Springs Capital Management LP now owns 1,400,000 shares of the company’s stock valued at $3,374,000 after purchasing an additional 610,520 shares during the period. Deutsche Bank AG grew its position in Obseva by 345.8% during the first quarter. Deutsche Bank AG now owns 109,554 shares of the company’s stock worth $264,000 after buying an additional 84,980 shares in the last quarter. California Public Employees Retirement System bought a new position in shares of Obseva in the second quarter worth $401,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Obseva by 63.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 156,944 shares of the company’s stock worth $378,000 after purchasing an additional 61,021 shares during the period. Hedge funds and other institutional investors own 48.54% of the company’s stock.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Recommended Story: Can systematic risk be avoided?

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.